Ustekinumab for Intestinal Behçet's Disease: The First Cohort with a Novel Therapy

IF 2.7 3区医学 Q3 GASTROENTEROLOGY & HEPATOLOGY

Journal of Digestive Diseases Pub Date : 2026-09-09 Epub Date: 2026-07-07 DOI:10.1111/1751-2980.70059

Hong Sheng Yang, Ze Fang Xia, Chu Rong Lin, Zhao Peng Huang, Xiang Gao, Miao Li, Pin Jin Hu

{"title":"Ustekinumab for Intestinal Behçet's Disease: The First Cohort with a Novel Therapy","authors":"Hong Sheng Yang, Ze Fang Xia, Chu Rong Lin, Zhao Peng Huang, Xiang Gao, Miao Li, Pin Jin Hu","doi":"10.1111/1751-2980.70059","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objectives</h3>\n \n <p>Evidence-based treatments for intestinal Behçet's disease (BD) remain limited. There is an unmet need for the development of effective therapies for refractory cases. We aimed to evaluate the safety and efficacy of ustekinumab, an anti-interleukin (IL)-12/23 monoclonal antibody, for intestinal BD treatment.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A retrospective cohort study was conducted on intestinal BD patients who received ≥ 1 dose of ustekinumab and had ≥ 3-month follow-up. The primary outcome was clinical response at 3 months. Secondary outcomes included clinical remission at 3, 6, and 12 months, endoscopic/radiologic/ultrasound responses and remissions, mucosal healing, and safety profiles.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Sixteen patients were enrolled, among whom 87.5% and 68.8% achieved clinical response and clinical remission at 3 months. At 6 months, 72.7% (8/11) of patients achieved clinical response and 45.5% (5/11) achieved clinical remission. In addition, 80.0% (8/10) had endoscopic response, 70.0% (7/10) achieved mucosal healing, 87.5% (7/8) had radiologic response, and 55.6% (5/9) had ultrasound response, respectively. At 12 months, 85.7% (6/7) patients achieved both clinical response and remission, with 100% endoscopic response, 83.4% mucosal healing, 100% (5/5) ultrasound response, 40.0% (2/5) ultrasound remission, 66.7% (2/3) radiologic response and remission. All five steroid users at baseline discontinued corticosteroids by 6 months. Only 18.8% (3/16) experienced self-limiting adverse events, and no patient discontinued treatment due to adverse events.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Ustekinumab appears to be an effective, well-tolerated treatment for intestinal BD, particularly for refractory cases.</p>\n </section>\n </div>","PeriodicalId":15564,"journal":{"name":"Journal of Digestive Diseases","volume":"27 5-6","pages":"234-242"},"PeriodicalIF":2.7000,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Digestive Diseases","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/1751-2980.70059","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/7/7 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives

Evidence-based treatments for intestinal Behçet's disease (BD) remain limited. There is an unmet need for the development of effective therapies for refractory cases. We aimed to evaluate the safety and efficacy of ustekinumab, an anti-interleukin (IL)-12/23 monoclonal antibody, for intestinal BD treatment.

Methods

A retrospective cohort study was conducted on intestinal BD patients who received ≥ 1 dose of ustekinumab and had ≥ 3-month follow-up. The primary outcome was clinical response at 3 months. Secondary outcomes included clinical remission at 3, 6, and 12 months, endoscopic/radiologic/ultrasound responses and remissions, mucosal healing, and safety profiles.

Results

Sixteen patients were enrolled, among whom 87.5% and 68.8% achieved clinical response and clinical remission at 3 months. At 6 months, 72.7% (8/11) of patients achieved clinical response and 45.5% (5/11) achieved clinical remission. In addition, 80.0% (8/10) had endoscopic response, 70.0% (7/10) achieved mucosal healing, 87.5% (7/8) had radiologic response, and 55.6% (5/9) had ultrasound response, respectively. At 12 months, 85.7% (6/7) patients achieved both clinical response and remission, with 100% endoscopic response, 83.4% mucosal healing, 100% (5/5) ultrasound response, 40.0% (2/5) ultrasound remission, 66.7% (2/3) radiologic response and remission. All five steroid users at baseline discontinued corticosteroids by 6 months. Only 18.8% (3/16) experienced self-limiting adverse events, and no patient discontinued treatment due to adverse events.

Conclusion

Ustekinumab appears to be an effective, well-tolerated treatment for intestinal BD, particularly for refractory cases.

查看原文本刊更多论文

Ustekinumab治疗肠beharret病：首个新疗法队列

目的：以证据为基础的肠道behaperet病（BD）治疗仍然有限。对难治性病例开发有效疗法的需求尚未得到满足。我们旨在评估ustekinumab（一种抗白细胞介素(IL)-12/23单克隆抗体）治疗肠道BD的安全性和有效性。方法：对接受≥1剂ustekinumab治疗且随访≥3个月的肠道BD患者进行回顾性队列研究。主要终点是3个月时的临床反应。次要结局包括3、6和12个月的临床缓解，内窥镜/放射学/超声反应和缓解，粘膜愈合和安全性。结果：16例患者入组，其中87.5%和68.8%的患者在3个月时达到临床缓解和缓解。6个月时，72.7%（8/11）的患者达到临床缓解，45.5%（5/11）的患者达到临床缓解。内镜下有效率为80.0%(8/10)，黏膜愈合率为70.0%(7/10)，影像学有效率87.5%(7/8)，超声有效率55.6%（5/9）。12个月时，85.7%（6/7）的患者达到临床缓解和缓解，其中内镜下100%缓解，黏膜愈合83.4%，超声100%(5/5)，超声缓解40.0%(2/5)，放射学缓解66.7%（2/3）。基线时所有5名类固醇使用者均在6个月前停用皮质类固醇。仅有18.8%（3/16）的患者出现了自限性不良事件，且没有患者因不良事件而中断治疗。结论：Ustekinumab似乎是一种有效的、耐受性良好的治疗肠道BD的方法，特别是对于难治性病例。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Digestive Diseases 医学-胃肠肝病学

CiteScore

5.40

自引率

2.90%

发文量

审稿时长

6-12 weeks

期刊介绍： The Journal of Digestive Diseases is the official English-language journal of the Chinese Society of Gastroenterology. The journal is published twelve times per year and includes peer-reviewed original papers, review articles and commentaries concerned with research relating to the esophagus, stomach, small intestine, colon, liver, biliary tract and pancreas.